[Vista Pharmaceuticals, Inc.]
|Category||DEA Schedule||Marketing Status|
|HUMAN PRESCRIPTION DRUG LABEL||unapproved drug other|
lsoxsuprine HCI occurs as a white odorless, crystalline powder, having a bitter
taste, It has a following structural formula
Based on a review of this drug by the National Academy of Sciences -National Research Council and / or other information, the FDA has classified the medications as follows :
Possibly Effective :
1. For the relief of symptoms associated with cerebral vascular insufficiency
2. In peripheral vascular disease of arteriosclerosis obliterans, thromboangitis obliterans (Buerger's Disease) and Raynaud's disease.
Final classification of the less than - effective indications requires further investigation.
CONTRAINDICATIONS AND CAUTIONS
There are no known contraindications to oral use when administered in recommended doses. Should not be given immediately postpartum or in the presence of arterial bleeding.
On rare occasions oral administration of the drug has been associated in time with the occurrences of hypotension, tachycardia, nausea, vomiting, dizziness, abdominal distress, and severe rash. If rash appears the drug should be discontinued.
Although available evidence suggests a temporal association of these reactions with Isoxsuprine, a casual relationship can be neither confirmed nor refused.
isoxsuprine hydrochloride tablet
|Labeler - Vista Pharmaceuticals, Inc. (943932806)|
|Vista Pharmaceuticals, Limited.||916648541||manufacture(61971-065), analysis(61971-065)|